Scientific Advisory Board

Dr. Chris Bahl is the Head of Protein Design at the Institute for Protein Innovation in Boston, USA. His non-profit research group develops and combines computational protein design with automated high-throughput laboratory technologies to accelerate drug discovery and to engineer lead therapeutic molecules.

Dr. John Gabrielson is the vice president of analytical sciences at KBI Biopharma. His main research interests are biophysics, particle characterization, analytical method capability, simulation & modelling. Dr. Gabrielson co-founded Elion Labs before it was acquired by KBI Biopharma.

Dr. Meier is a Professor at the University of Miami, Department of Chemistry. Her research focuses on achieving a better understanding of the reported roles of copper and iron proteins as contributors to neurodegenerative disease progression, cancer metastasis and chemoresistance, and drug resistant infections.

Dr. Russ Middaugh is a distinguished professor at the University of Kansas. His main research interests are the stability of proteins, DNA, macromolecular assemblies, virus-like particles, viruses, and bacterial cells for pharmaceutical use. He runs the macromolecule and vaccine stabilization center at the university.

Dr. Sandro Keller is a professor of biophysics at the Institute of Molecular Biosciences (IMB) of the University of Graz, Austria. His main research interests are membrane proteins and lipids as well as membrane-mimetic systems, with a focus on polymer-encapsulated nanodiscs.

Dr. Teddy Zartler is director of biopharma service for US at SGS. He obtained his BS from Goucher College and PhD from UPenn. Dr. Zartler has 29 peer-reviewed publications and edited two books: Fragment-Based Drug Discovery, and Applied Biophysics for Drug Discovery.